Type 1 Diabetes - Pipeline Insight, 2025
Description
DelveInsight’s, “Type 1 Diabetes - Pipeline Insight, 2025” report provides comprehensive insights about 85+ companies and 100+ pipeline drugs in Type 1 Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Type 1 Diabetes: Overview
Type 1 diabetes is an autoimmune disease where the body's immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. This results in a complete lack of insulin production, which is required for the body to regulate blood sugar levels. The exact cause of this autoimmune destruction is unknown, but it is believed to involve a combination of genetic and environmental factors.
Genetic factors play a significant role, as having a first-degree relative (parent or sibling) with type 1 diabetes increases the risk of developing the disease. Certain genes have also been linked to an increased susceptibility. Environmental triggers, such as viral infections, exposure to certain chemicals, or dietary factors like cow's milk, may also contribute to the autoimmune response that leads to beta cell destruction. However, the specific trigger that initiates this process remains unclear. The 10-30% of cases where no autoimmunity is detected are classified as idiopathic type 1 diabetes, and the cause in these instances is unknown.
The most common symptoms of type 1 diabetes include increased thirst, frequent urination (especially at night), extreme hunger, unintended weight loss, fatigue and weakness, blurred vision, irritability, and other mood changes. Additional signs may include genital itching or thrush, cuts and wounds that take longer to heal, and fruity-smelling breath. In children, symptoms can also manifest as heavier diapers, bed-wetting in previously potty-trained kids, fast breathing, belly pain, vomiting, and behavior changes. The symptoms often appear suddenly, especially in children, and can progress rapidly over days or weeks as the pancreas produces less and less insulin. Prompt diagnosis and treatment are crucial, as untreated type 1 diabetes can lead to life-threatening diabetic ketoacidosis.
The primary treatment for type 1 diabetes is insulin therapy, which involves administering insulin via injections or an insulin pump to regulate blood sugar levels. Insulin is essential for people with type 1 diabetes as their pancreas is unable to produce it. Carbohydrate counting is also crucial to match insulin doses with the amount of carbs consumed. Continuous glucose monitoring (CGM) or flash glucose monitoring can help track blood sugar levels without frequent finger prick tests. Other medications like metformin may sometimes be prescribed in addition to insulin. Maintaining a healthy diet, regular physical activity, and achieving a healthy weight are important lifestyle factors that help manage type 1 diabetes. Regular check-ups with the diabetes care team, including an endocrinologist, certified diabetes educator, and registered dietitian, are necessary to monitor the condition and adjust treatment as needed.
""Type 1 Diabetes - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Type 1 Diabetes pipeline landscape is provided which includes the disease overview and Type 1 Diabetes treatment guidelines. The assessment part of the report embraces, in depth Type 1 Diabetes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Type 1 Diabetes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Type 1 Diabetes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Type 1 Diabetes Emerging Drugs
Further product details are provided in the report……..
Type 1 Diabetes: Therapeutic Assessment
This segment of the report provides insights about the different Type 1 Diabetes drugs segregated based on following parameters that define the scope of the report, such as:
Type 1 Diabetes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Type 1 Diabetes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 1 Diabetes drugs.
Type 1 Diabetes Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Type 1 Diabetes: Overview
Type 1 diabetes is an autoimmune disease where the body's immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. This results in a complete lack of insulin production, which is required for the body to regulate blood sugar levels. The exact cause of this autoimmune destruction is unknown, but it is believed to involve a combination of genetic and environmental factors.
Genetic factors play a significant role, as having a first-degree relative (parent or sibling) with type 1 diabetes increases the risk of developing the disease. Certain genes have also been linked to an increased susceptibility. Environmental triggers, such as viral infections, exposure to certain chemicals, or dietary factors like cow's milk, may also contribute to the autoimmune response that leads to beta cell destruction. However, the specific trigger that initiates this process remains unclear. The 10-30% of cases where no autoimmunity is detected are classified as idiopathic type 1 diabetes, and the cause in these instances is unknown.
The most common symptoms of type 1 diabetes include increased thirst, frequent urination (especially at night), extreme hunger, unintended weight loss, fatigue and weakness, blurred vision, irritability, and other mood changes. Additional signs may include genital itching or thrush, cuts and wounds that take longer to heal, and fruity-smelling breath. In children, symptoms can also manifest as heavier diapers, bed-wetting in previously potty-trained kids, fast breathing, belly pain, vomiting, and behavior changes. The symptoms often appear suddenly, especially in children, and can progress rapidly over days or weeks as the pancreas produces less and less insulin. Prompt diagnosis and treatment are crucial, as untreated type 1 diabetes can lead to life-threatening diabetic ketoacidosis.
The primary treatment for type 1 diabetes is insulin therapy, which involves administering insulin via injections or an insulin pump to regulate blood sugar levels. Insulin is essential for people with type 1 diabetes as their pancreas is unable to produce it. Carbohydrate counting is also crucial to match insulin doses with the amount of carbs consumed. Continuous glucose monitoring (CGM) or flash glucose monitoring can help track blood sugar levels without frequent finger prick tests. Other medications like metformin may sometimes be prescribed in addition to insulin. Maintaining a healthy diet, regular physical activity, and achieving a healthy weight are important lifestyle factors that help manage type 1 diabetes. Regular check-ups with the diabetes care team, including an endocrinologist, certified diabetes educator, and registered dietitian, are necessary to monitor the condition and adjust treatment as needed.
""Type 1 Diabetes - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Type 1 Diabetes pipeline landscape is provided which includes the disease overview and Type 1 Diabetes treatment guidelines. The assessment part of the report embraces, in depth Type 1 Diabetes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Type 1 Diabetes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Type 1 Diabetes R&D. The therapies under development are focused on novel approaches to treat/improve Type 1 Diabetes.
This segment of the Type 1 Diabetes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Type 1 Diabetes Emerging Drugs
- Insulin Efsitora Alfa: Eli Lilly and Company
- Stem Cell Educator therapy: Throne Biotechnologies
- Frexalimab: Sanofi
- VX-880: Vertex Pharmaceuticals
- MTX-101: Mozart Therapeutics
Further product details are provided in the report……..
Type 1 Diabetes: Therapeutic Assessment
This segment of the report provides insights about the different Type 1 Diabetes drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Type 1 Diabetes
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Type 1 Diabetes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Type 1 Diabetes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 1 Diabetes drugs.
Type 1 Diabetes Report Insights
- Type 1 Diabetes Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Type 1 Diabetes drugs?
- How many Type 1 Diabetes drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Type 1 Diabetes?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Type 1 Diabetes therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Type 1 Diabetes and their status?
- What are the key designations that have been granted to the emerging drugs?
- Eli Lilly and Company
- Throne Biotechnologies
- Sanofi
- Vertex Pharmaceuticals
- Mozart Therapeutics
- Zealand Pharma
- Adocia
- Creative Medical Technology Holdings
- Sernova
- Boehringer Ingelheim
- Bayer
- Tiziana Life Sciences
- Amarna Therapeutics
- PolTREG
- Surrozen
- Biomea Fusion
- ITBMed Biopharmaceuticals
- Panbela Therapeutics
- Diamyd Medical
- Insulin Efsitora Alfa
- Stem Cell Educator Therapy
- Frexalimab
- VX-880
- MTX-101
- Dasiglucagon
- BioChaperone Lispro
- CELZ-201
- Islet cell replacement therapy
- Empagliflozin
- Finerenone
- Foralumab
- AM-510
- PTG-020
- Research programme
- BMF-219
- Siplizumab
- Eflornithine
- Diamyd
Table of Contents
240 Pages
- Introduction
- Executive Summary
- Type 1 Diabetes: Overview
- Causes
- Etiology
- Signs and Symptoms
- Disease Treatment/Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Type 1 Diabetes– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Insulin Efsitora Alfa: Eli Lilly and Company
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Frexalimab: Sanofi
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- MTX-101: Mozart Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Type 1 Diabetes Key Companies
- Type 1 Diabetes Key Products
- Type 1 Diabetes- Unmet Needs
- Type 1 Diabetes- Market Drivers and Barriers
- Type 1 Diabetes- Future Perspectives and Conclusion
- Type 1 Diabetes Analyst Views
- Type 1 Diabetes Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
